The only documents it eventually produced were an appeal letter, the plan certificate, and the denial notice none of which addressed the core issue: why Zepbound was excluded for OSA
Given these potential side effects, RELATED QUESTIONS
insulin glargine and liraglutide for the treatment of type 2 diabetes mellitus in Greece
[6] [7] The glucagon receptor component of retatrutide may influence energy expenditure and thermogenesis based on preclinical and physiological studies, but the clinical relevance of this effect on perceived body temperature in humans remains under investigation and should not be overstated
GLP-1 medications improve insulin sensitivity in liver cells, reduce oxidative stress, and activate cellular cleaning processes like macroautophagy that help remove excess fat 19
The ongoing Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2F3) MASH and the Phase 3 ENLIGHTEN-Cirrhosis trial in compensated cirrhotic (F4) MASH are actively enrolling patients